Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
04 Jun 2024
Historique:
received: 17 02 2023
revised: 29 12 2023
accepted: 05 04 2024
medline: 4 6 2024
pubmed: 4 6 2024
entrez: 4 6 2024
Statut: ppublish

Résumé

Cancer cells exhibit metabolic plasticity to meet oncogene-driven dependencies while coping with nutrient availability. A better understanding of how systemic metabolism impacts the accumulation of metabolites that reprogram the tumor microenvironment (TME) and drive cancer could facilitate development of precision nutrition approaches. Using the Hi-MYC prostate cancer mouse model, we demonstrated that an obesogenic high-fat diet (HFD) rich in saturated fats accelerates the development of c-MYC-driven invasive prostate cancer through metabolic rewiring. Although c-MYC modulated key metabolic pathways, interaction with an obesogenic HFD was necessary to induce glycolysis and lactate accumulation in tumors. These metabolic changes were associated with augmented infiltration of CD206+ and PD-L1+ tumor-associated macrophages (TAM) and FOXP3+ regulatory T cells, as well as with the activation of transcriptional programs linked to disease progression and therapy resistance. Lactate itself also stimulated neoangiogenesis and prostate cancer cell migration, which were significantly reduced following treatment with the lactate dehydrogenase inhibitor FX11. In patients with prostate cancer, high saturated fat intake and increased body mass index were associated with tumor glycolytic features that promote the infiltration of M2-like TAMs. Finally, upregulation of lactate dehydrogenase, indicative of a lactagenic phenotype, was associated with a shorter time to biochemical recurrence in independent clinical cohorts. This work identifies cooperation between genetic drivers and systemic metabolism to hijack the TME and promote prostate cancer progression through oncometabolite accumulation. This sets the stage for the assessment of lactate as a prognostic biomarker and supports strategies of dietary intervention and direct lactagenesis blockade in treating advanced prostate cancer. Lactate accumulation driven by high-fat diet and MYC reprograms the tumor microenvironment and promotes prostate cancer progression, supporting the potential of lactate as a biomarker and therapeutic target in prostate cancer. See related commentary by Frigo, p. 1742.

Identifiants

pubmed: 38831751
pii: 745520
doi: 10.1158/0008-5472.CAN-23-0519
doi:

Substances chimiques

Lactic Acid 33X04XA5AT
Proto-Oncogene Proteins c-myc 0
MYC protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1834-1855

Subventions

Organisme : AIRC Foundation for Cancer Research
ID : IG-21966
Organisme : Canadian Institutes of Health Research (CIHR)
ID : PJT-180368
Organisme : Canadian Institutes of Health Research (CIHR)
ID : PJT-162246
Organisme : Dana-Farber Cancer Institute (DFCI)
ID : Claudia Adams Barr Award in Innovative Basic Cancer Research
Organisme : U.S. Department of Defense (DOD)
ID : PC150263
Organisme : World Cancer Research Fund International (WCRF)
ID : IIG_FULL_2022_020

Informations de copyright

©2024 The Authors; Published by the American Association for Cancer Research.

Auteurs

Nadia Boufaied (N)

Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.

Paolo Chetta (P)

University of Milan, Residency Program in Pathology, Milan, Italy.
Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.

Tarek Hallal (T)

Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.
Department of Anatomy and Cell Biology, McGill University, Montréal, Québec, Canada.

Stefano Cacciatore (S)

Bionformatics Unit, International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town, South Africa.

Daniela Lalli (D)

Department of Science and Technological Innovation, University of Piemonte Orientale "A. Avogadro," Alessandria, Italy.

Carole Luthold (C)

CHU de Québec-Université Laval Research Center (Oncology Division) and Cancer Research Center, Centre de Recherche en Organogénèse Expérimentale/LOEX, Université Laval, Québec, Canada.

Kevin Homsy (K)

CHU de Québec-Université Laval Research Center (Oncology Division) and Cancer Research Center, Centre de Recherche en Organogénèse Expérimentale/LOEX, Université Laval, Québec, Canada.

Eddie L Imada (EL)

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York Presbyterian-Weill Cornell Campus, New York, New York.

Sudeepa Syamala (S)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Cornelia Photopoulos (C)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Anna Di Matteo (A)

Institute of Molecular Genetics, National Research Council (CNR-IGM), Pavia, Italy.

Anna de Polo (A)

Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.

Alessandra Maria Storaci (AM)

Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

Ying Huang (Y)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Francesca Giunchi (F)

Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Patricia A Sheridan (PA)

Metabolon Inc., Morrisville, North Carolina.

Gregory Michelotti (G)

Metabolon Inc., Morrisville, North Carolina.

Quang-De Nguyen (QD)

Department of Imaging, Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Xin Zhao (X)

Veracyte, South San Francisco, California.

Yang Liu (Y)

Veracyte, South San Francisco, California.

Elai Davicioni (E)

Veracyte, South San Francisco, California.

Daniel E Spratt (DE)

Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.

Simone Sabbioneda (S)

Institute of Molecular Genetics, National Research Council (CNR-IGM), Pavia, Italy.

Giovanni Maga (G)

Institute of Molecular Genetics, National Research Council (CNR-IGM), Pavia, Italy.

Lorelei A Mucci (LA)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Claudia Ghigna (C)

Institute of Molecular Genetics, National Research Council (CNR-IGM), Pavia, Italy.

Luigi Marchionni (L)

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York Presbyterian-Weill Cornell Campus, New York, New York.

Lisa M Butler (LM)

South Australian Immunogenomics Cancer Institute and Freemasons Centre for Male Health and Wellbeing, University of Adelaide, South Australian Health and Medical Research Institute, Adelaide, Australia.

Leigh Ellis (L)

Department of Surgery, Center for Prostate Disease Research, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland.

François Bordeleau (F)

CHU de Québec-Université Laval Research Center (Oncology Division) and Cancer Research Center, Centre de Recherche en Organogénèse Expérimentale/LOEX, Université Laval, Québec, Canada.
Department of Molecular Biology, Clinical Biochemistry, and Pathology, Laval University, Québec, Canada.

Massimo Loda (M)

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York Presbyterian-Weill Cornell Campus, New York, New York.

Valentina Vaira (V)

Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

David P Labbé (DP)

Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.
Department of Anatomy and Cell Biology, McGill University, Montréal, Québec, Canada.
Division of Urology, Department of Surgery, McGill University, Montréal, Québec, Canada.

Giorgia Zadra (G)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Institute of Molecular Genetics, National Research Council (CNR-IGM), Pavia, Italy.
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH